Additional disease indications have been described where inhibition of inflammatory TNFR1 activity, while maintaining TNFR2-associated Treg suppressive activity, might be beneficial, e. g. type-1 diabetes [8], heart failure [31] and multiple sclerosis [32]. Here, TNFRSF1B is linked to heart failure.